Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment

CXCR4 engagement by amines leads to the control of IFN signaling in pDCs and opens new therapeutic perspectives in Lupus patients. Type I interferons are highly potent cytokines essential for self-protection against tumors and infections. Deregulations of type I interferon signaling are associated with multiple diseases that require novel therapeutic options. Here, we identified the small molecule, IT1t, a previously described CXCR4 ligand, as a highly potent inhibitor of Toll-like receptor 7 (TLR7)–mediated inflammation. IT1t inhibits chemical (R848) and natural (HIV) TLR7-mediated inflammation in purified human plasmacytoid dendritic cells from blood and human tonsils. In a TLR7-dependent lupus-like model, in vivo treatment of mice with IT1t drives drastic reduction of both systemic inflammation and anti–double-stranded DNA autoantibodies and prevents glomerulonephritis. Furthermore, IT1t controls inflammation, including interferon α secretion, in resting and stimulated cells from patients with systemic lupus erythematosus. Our findings highlight a groundbreaking immunoregulatory property of CXCR4 signaling that opens new therapeutic perspectives in inflammatory settings and autoimmune diseases.

[1]  Yoshiya Tanaka,et al.  Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus , 2018, Front. Immunol..

[2]  J. Gottenberg,et al.  The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. , 2018, Autoimmunity reviews.

[3]  S. Sozzani,et al.  Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7. , 2018, JCI insight.

[4]  J. van Grevenynghe,et al.  Sustained IFN-I Expression during Established Persistent Viral Infection: A “Bad Seed” for Protective Immunity , 2017, Viruses.

[5]  Joshua B. Singer,et al.  Fundamental properties of the mammalian innate immune system revealed by multispecies comparison of type I interferon responses , 2017, PLoS biology.

[6]  K. Yamaji,et al.  Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus , 2017, Arthritis Research & Therapy.

[7]  F. Rieux-Laucat,et al.  Detection of interferon alpha protein reveals differential levels and cellular sources in disease , 2017, The Journal of experimental medicine.

[8]  Pasquale Cutolo,et al.  Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement , 2017, Nature Communications.

[9]  M. Carrillo,et al.  Targeting type I interferon–mediated activation restores immune function in chronic HIV infection , 2017, The Journal of clinical investigation.

[10]  Zhiyuan Hu,et al.  Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs , 2017, The Journal of clinical investigation.

[11]  R. Sékaly,et al.  The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure? , 2017, The Journal of clinical investigation.

[12]  Y. Crow,et al.  Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview , 2016, The Journal of experimental medicine.

[13]  B. L. de Groot,et al.  CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.

[14]  Q. Lu,et al.  The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus. , 2016, International immunopharmacology.

[15]  Hedi Peterson,et al.  AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies , 2016, Cell.

[16]  L. Platanias,et al.  Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists , 2016, Scientific Reports.

[17]  P. Vidalain,et al.  An efficient method for gene silencing in human primary plasmacytoid dendritic cells: silencing of the TLR7/IRF-7 pathway as a proof of concept , 2016, Scientific Reports.

[18]  Ling Lin,et al.  Development of pristane induced mice model for lupus with atherosclerosis and analysis of TLR expression. , 2016, Clinical and experimental rheumatology.

[19]  V. Pascual,et al.  Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus , 2016, The Journal of experimental medicine.

[20]  Virginia Pascual,et al.  Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients , 2016, Cell.

[21]  Nan Yan,et al.  Response to Comment on “Cutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Mice” , 2016, The Journal of Immunology.

[22]  Nan Yan,et al.  Cutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Mice , 2015, The Journal of Immunology.

[23]  John J. Irwin,et al.  ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..

[24]  M. Colonna,et al.  The multifaceted biology of plasmacytoid dendritic cells , 2015, Nature Reviews Immunology.

[25]  C. Szeto,et al.  Animal Models of Interferon Signature Positive Lupus , 2015, Front. Immunol..

[26]  E. Unanue,et al.  Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model , 2014, The Journal of experimental medicine.

[27]  V. D’Agati,et al.  Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus , 2014, The Journal of experimental medicine.

[28]  T. Niewold.  Type I Interferon in Human Autoimmunity , 2014, Front. Immunol..

[29]  Haoyang Zhuang,et al.  Toll‐like Receptor 7–Stimulated Tumor Necrosis Factor α Causes Bone Marrow Damage in Systemic Lupus Erythematosus , 2014, Arthritis & rheumatology.

[30]  L. Ivashkiv,et al.  Regulation of type I interferon responses , 2013, Nature Reviews Immunology.

[31]  A. Caflisch,et al.  Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics. , 2013, Bioorganic & medicinal chemistry letters.

[32]  P. Vidalain,et al.  Inhibition of Pyrimidine Biosynthesis Pathway Suppresses Viral Growth through Innate Immunity , 2013, PLoS pathogens.

[33]  P. Desprès,et al.  Dengue Virus Activates Membrane TRAIL Relocalization and IFN-α Production by Human Plasmacytoid Dendritic Cells In Vitro and In Vivo , 2013, PLoS neglected tropical diseases.

[34]  Nouri Neamati,et al.  Small Molecule Inhibitors of CXCR4 , 2013, Theranostics.

[35]  V. Eraković Haber,et al.  Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype. , 2012, Cellular immunology.

[36]  R. Leurs,et al.  Pharmacological modulation of chemokine receptor function , 2012, British journal of pharmacology.

[37]  VINCENT ZOETE,et al.  SwissParam: A fast force field generation tool for small organic molecules , 2011, J. Comput. Chem..

[38]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[39]  V. Pascual,et al.  TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus , 2010, Nature.

[40]  A. Nademanee,et al.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  C. Mohan,et al.  Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus , 2009, Expert opinion on therapeutic targets.

[42]  P. Igarashi,et al.  CXCR4/CXCL12 Hyperexpression Plays a Pivotal Role in the Pathogenesis of Lupus1 , 2009, The Journal of Immunology.

[43]  Trixie Wagner,et al.  Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. , 2008, Journal of medicinal chemistry.

[44]  V. Pascual,et al.  The innate immune system in SLE: type I interferons and dendritic cells , 2008, Lupus.

[45]  L. Moldawer,et al.  A Novel Type I IFN-Producing Cell Subset in Murine Lupus1 , 2008, The Journal of Immunology.

[46]  S. Akira,et al.  Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. , 2008, Arthritis and rheumatism.

[47]  B. Pulendran,et al.  Improving Defences at the Portal of HIV Entry: Mucosal and Innate Immunity , 2008, PLoS medicine.

[48]  D. Graham,et al.  HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-α , 2007, Proceedings of the National Academy of Sciences.

[49]  M. Colonna,et al.  Crosspresentation: plasmacytoid dendritic cells are in the business. , 2007, Immunity.

[50]  Dominique Schols,et al.  Molecular Mechanism of Action of Monocyclam Versus Bicyclam Non-peptide Antagonists in the CXCR4 Chemokine Receptor* , 2007, Journal of Biological Chemistry.

[51]  V. Pascual,et al.  Type I interferon in systemic lupus erythematosus and other autoimmune diseases. , 2006, Immunity.

[52]  M. Kruhlak,et al.  Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[54]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  K. Lindblad-Toh,et al.  Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals , 2005, Nature.

[56]  J. Lifson,et al.  TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. , 2005, Blood.

[57]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[58]  Mette M. Rosenkilde,et al.  Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.

[59]  V. Pascual,et al.  The central role of dendritic cells and interferon-&agr; in SLE , 2003 .

[60]  Persephone Borrow,et al.  Viral infection switches non-plasmacytoid dendritic cells into high interferon producers , 2003, Nature.

[61]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[62]  N. Kadowaki,et al.  Natural type I interferon-producing cells as a link between innate and adaptive immunity. , 2002, Human immunology.

[63]  Antonio Lanzavecchia,et al.  Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells , 2001, European journal of immunology.

[64]  L. Nilsson,et al.  Structure and Dynamics of the TIP3P, SPC, and SPC/E Water Models at 298 K , 2001 .

[65]  R. Skeel,et al.  Langevin stabilization of molecular dynamics , 2001 .

[66]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[67]  T. Witte,et al.  Prognostic parameters for flare in systemic lupus erythematosus. , 2000, Rheumatology.

[68]  N. Kadowaki,et al.  The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.

[69]  J. Banchereau,et al.  The Enigmatic Plasmacytoid T Cells Develop into Dendritic Cells with Interleukin (IL)-3 and CD40-Ligand , 1997, The Journal of experimental medicine.

[70]  A. Garg,et al.  Type I interferons and dendritic cells in cancer immunotherapy. , 2019, International review of cell and molecular biology.

[71]  C. Gordon,et al.  Systemic lupus erythematosus , 2016, Nature Reviews Disease Primers.

[72]  V. Pascual,et al.  The central role of dendritic cells and interferon-alpha in SLE. , 2003, Current opinion in rheumatology.

[73]  S. Dzik.  The nature of the principal type 1 interferon-producing cells in human blood , 2000 .

[74]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.